ENA0000GenomicsLouis M Staudt, Lymphoid Malignancies Branch, National Cancer Institutehttps://www.ebi.ac.uk/ena/browser/view/PRJNA107335Homo sapiensGene expression profiling of DLBCL patient samples was performed to investigate, whether molecular gene expression signatures retain their prognostic significance in patients treated with chemotherapy plus Rituximab. The lymphnode, germinal center signature and a new angiogenesis signature were combined to a final multivariate model which defined quartile groups among Rituximab-CHOP-treated patients with distinct 3-year overall survival rates. Keywords: clinical history design Overall design: The retrospective study included 181 clinical samples from CHOP-treated patients and 233 clinical samples from Rituximab-CHOP-treated patients.ENAbig, B Cells, Rituxan, diffuse, gyltl1b-b, B Lymphocytes, Rituximab CD20 Antibody, Bursa-Dependent Lymphocytes, malignant, B cell, Mbp1, adult lymphoma, IDEC C2B8, Germinoblastoma, Malignant, Germinoblastic Sarcoma, froggy, Gyltl1a, lymphoma (Hodgkin's and non-Hodgkin's), Malignant Lymphomas, large, Reticulolymphosarcomas, survival, Rituximab, MDDGA6, mKIAA0609, GP2013., Chemotherapy, Germinoblastic Sarcomas, Germinoblastic, Mabthera, myd, Lymphomas, malignant lymphoma, Reticulolymphosarcoma, lymphomatous, CD20 Antibody, fg, Sarcomas, B-cell, gyltl1b, lymphoma (Hodgkin and non-Hodgkin), MDDGB6, IDEC-C2B8 Antibody, scattered, mdc1d, expanded, Mbp-1, Bursa-Equivalent Lymphocyte, IDEC-C2B8, MLYM, Germinoblastomas, BPFD#36, MDC1D, Malignant Lymphoma, Sarcoma, lymphoma, enr, B lymphocyte, enlarged, B-Lymphocyte, time of survival, great, Lymphoma, lymphoma of adults, B-lymphocyte, IDEC C2B8 Antibody, lymphoid cancerhuman being, human., man0.00.00.00.00.00falseHomo sapiensPrediction of survival in diffuse large B cell lymphoma treated with chemotherapy plus Rituximab2022-05-122014-02-11PRJNA107335GSE1084619038878215465049606